Prestige Brands Holdings, Inc. Stock News

Prestige Consumer Healthcare Inc. (NYSE:PBH ) Barclays 18th Annual Global Consumer Staples Conference 2025 September 4, 2025 12:45 PM EDT Company Participants Ron Lombardi - Chairman, President & CEO Christine Sacco - CFO & COO Presentation Ron Lombardi Chairman, President & CEO Okay. Good afternoon, everyone.

TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Barclays Global Consumer Staples Conference on Thursday, September 4, 2025 at 12:45 p.m. ET. All interested parties may access a live webcast of this event at www.prestigeconsumerhealthcare.com under the “Investors” section and the “Events and Presentations” ta...

Premium Brands continues steady mid-single-digit organic growth, with Q2 revenue up 12.4% year-over-year, but faces margin pressure from higher interest and investment cycle. The company's high leverage (Debt/EBITDA ~4x) and ongoing M&A strategy weigh on net profit and cash flow, despite improved free cash flow this quarter. Long-term targets are ambitious ($10B revenue, $1–1.2B EBITDA by FY 20...

Prestige Consumer Healthcare Inc. (NYSE:PBH ) Q1 2026 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Christine Sacco - CFO & COO Philip David Terpolilli - Director of Investor Relations Ronald M. Lombardi - Chairman, President & CEO Conference Call Participants Anthony Chester Lebiedzinski - Sidoti & Company, LLC Douglas Matthai Lane - Water Tower Research LLC Glenn Wes...

Prestige Consumer Healthcare (PBH 1.51%), the over-the-counter (OTC) healthcare product company behind brands such as Clear Eyes, Monistat, and Chloraseptic, released its first-quarter results for fiscal 2026 on August 7, 2025. The most vital news was that GAAP revenue and earnings per share both fell short of expectations, mainly due to supply constraints in its North American Eye & Ear Care b...

Revenue of $249.5 million in Q1; decline driven by limited eye care supply Diluted EPS of $0.95 in Q1, up approximately 6% versus prior year Adjusted Diluted EPS of $0.90 Announces agreement to acquire current eye care supplier Pillar5 Pharma Revising fiscal 2026 revenue outlook to $1,100 to $1,115 million and Diluted EPS outlook to $4.50 to $4.58 TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE)...

TARRYTOWN, N.Y., July 15, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 first quarter earnings release on Thursday, August 7, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.

TARRYTOWN, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- Medtech Products Inc., a Prestige Consumer Healthcare Inc. company (“Medtech” or “Company”), is voluntarily recalling five lots of Little Remedies® Honey Cough Syrup (the “Product”) due to the presence of Bacillus cereus and loss of shelf-stability. Bacillus cereus (B. cereus) can cause two types of food-borne illnesses. One type is characteriz...